Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days

Influenza and other Respiratory Viruses

Volumn 7, Issue 5, 2013, Pages 833-837

  Ryoo, Seung M ^a   Kim, Won Y ^a   Sohn, Chang H ^a   Seo, Dong W ^a   Oh, Bum J ^a   Lee, Jae H ^a   Lee, Yoon S ^a   Lim, Kyoung S ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

H1N1 subtype; Influenza A virus; RT PCR; Viral shedding

Indexed keywords

OSELTAMIVIR;

2009 H1N1 INFLUENZA; ADULT; ANTIVIRAL THERAPY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS SHEDDING;

H1N1 SUBTYPE; INFLUENZA A VIRUS; RT-PCR; VIRAL SHEDDING;

ADULT; ANTIVIRAL AGENTS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; PANDEMICS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; VIRUS SHEDDING; YOUNG ADULT;

EID: 84882700673     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12065     Document Type: Article

References (27)

1. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. Harrison's principles of internal medicine, 6th edn. NewYork: McGraw-Hill, 2005.
2. World Health Organization. Global Alert and Response (GAR); Pandemic (H1N1) 2009 - Update. World Health Organization, 2009. Available at http://www.who.int/csr/don/2010_03_12/en/index.html (Accessed 12 March 2010).
3. Lee N, Chan PK, Hui DS et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492-500.
4. World Health Organization. Clinical Management of Human Infection with Pandemic (H1N1) 2009: Revised Guidance. World Health Organization, 2009. Available at http://www.who.int/csr/resources/publications/swineflu/clinical_management/en/index.html (Accessed 12 March 2010).
5. Itoh Y, Shinya K, Kiso M et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460:1021-1025.
6. Maines TR, Jayaraman A, Belser JA et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 2009; 325:484-487.
7. Munster VJ, de Wit E, van den Brand JM et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009; 325:481-483.
8. Witkop CT, Duffy MR, Macias EA et al. Novel Influenza A (H1N1) outbreak at the U.S. Air Force Academy: epidemiology and viral shedding duration. Am J Prev Med 2010; 38:121-126.
9. Eggertson L. Pandemic (H1N1) 2009 lives in some people for at least eight days after symptoms develop. CMAJ 2009; 181:E203.
10. To KK, Chan KH, Li IW et al. Viral load in patients infected with pandemic H1N1 2009 influenza A virus. J Med Virol 2010; 82:1-7.
11. Na S, Chong YP, Kim MN et al. Duration of viral shedding in patients admitted to hospital with pandemic influenza A/H1N1 2009 infection. J Med Virol 2011; 83:5-9.
12. Malato L, Llavador V, Marmier E et al. Pandemic influenza A(H1N1) 2009: molecular characterisation and duration of viral shedding in intensive care patients in Bordeaux, south-west France, May 2009 to January 2010. Euro Surveill 2011; 16:[pii: 19776].
13. Cao B, Li XW, Mao Y et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009; 361:2507-2517.
14. Ong AK, Chen MI, Lin L et al. Improving the clinical diagnosis of influenza-a comparative analysis of new influenza A (H1N1) cases. PLoS ONE 2009; 4:e8453.
15. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362:1733-1745.
16. Cox NJ, Subbarao K. Influenza. Lancet 1999; 354:1277-1282.
17. Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathkumar P. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007; 28:1071-1076.
18. Ling LM, Chow AL, Lye DC et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50:963-969.
19. Meschi S, Selleri M, Lalle E et al. Duration of viral shedding in hospitalized patients infected with pandemic H1N1. BMC Infect Dis 2011; 11:140.
20. CDC Recommendations for the Amount of Time Persons with Influenza-Like Illness Should be Away from Others. Atlanta, GA: Centers for Disease Control and Prevention, 2009 [updated October 23, 2009]. Available at http://www.cdc.gov/H1N1flu/guidance/exclusion.htm (Accessed 26 April 2010).
21. Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J 2005; 24:931-932.
22. Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016-1024.
23. Aoki FY, Boivin G. Influenza virus shedding: excretion patterns and effects of antiviral treatment. J Clin Virol 2009; 44:255-261.
24. Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355:1845-1850.
25. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361:680-689.
26. Li IW, Hung IF, To KK et al. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest 2010; 137:759-768.
27. Choi WJ, Kim WY, Kim SH et al. Clinical characteristics of pneumonia in hospitalized patients with novel influenza A (H1N1) in Korea. Scand J Infect Dis 2010; 42:311-314.